Literature DB >> 1770075

Factors influencing the protein binding of bumetanide using an equilibrium dialysis technique.

H J Shim1, M G Lee, M H Lee.   

Abstract

Factors that influence the plasma protein binding of bumetanide were evaluated using equilibrium dialysis. It took approximately 12 h of incubation to reach an equilibrium between plasma and isotonic phosphate buffer of pH 7.4 containing 3% dextran using a Spectrapor 2 membrane (mol. wt cut-off = 12,000-14,000) in a water-bath shaker kept at 37 degrees C and at a rate of 50 oscillations per min. Bumetanide was fairly stable in both 4% human serum albumin (HSA) and in the isotonic phosphate buffer of pH 7.4 for up to 24 h. The binding of bumetanide to 4% HSA was constant (87.5 +/- 1.73%) at bumetanide concentrations ranging from 0.1 to 100 micrograms/ml. The extents of binding were 72.0, 83.3, 88.5, 90.2, 91.3 and 91.4% at albumin concentrations of 0.5, 1, 2, 3, 4 and 5 g/100 ml, respectively, and increased with a decrease in incubation temperature; the values bound were 94.6, 90.3 and 89.3% when incubated at 4, 22 and 37 degrees C, respectively. The binding of bumetanide was independent of the buffer composition used, the quantities of AAG (up to 0.32%), heparin (up to 40 units/ml), sodium azide (up to 0.5%) and anticoagulants (EDTA, heparin and citrate). The free fraction of bumetanide in rabbit plasma (2.91%) was significantly higher than in humans (1.98%) or rats (1.85%).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1770075     DOI: 10.1111/j.1365-2710.1991.tb00337.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  4 in total

1.  Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.

Authors:  S H Lee; M G Lee; N D Kim
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

Review 2.  NKCC1, an Elusive Molecular Target in Brain Development: Making Sense of the Existing Data.

Authors:  Mari A Virtanen; Pavel Uvarov; Christian A Hübner; Kai Kaila
Journal:  Cells       Date:  2020-12-04       Impact factor: 6.600

Review 3.  Modulation of Urate Transport by Drugs.

Authors:  Péter Tátrai; Franciska Erdő; Gabriella Dörnyei; Péter Krajcsi
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321

Review 4.  Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures.

Authors:  Martin Puskarjov; Kristopher T Kahle; Eva Ruusuvuori; Kai Kaila
Journal:  Epilepsia       Date:  2014-05-06       Impact factor: 5.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.